AI holds immense promise for helping us bring medicines to patients faster, but only if we confront the growing data dilemma. Specifically, as we aim for AI to impact each step of the drug discovery and development process, satisfying the data requirements – in terms of quality, quantity, and diversity – is paramount to realizing this vision. In this panel, executives from MilliporeSigma, pharma, and leading tech bio companies will discuss how we intentionally design data generation processes to realize AI’s full potential, and how their organizations are using innovative platforms to address this challenge. Sponsored by: MilliporeSigma